Exelixis | EXEL - La Marge Brute Sur Les Ventes

Prix De L'Action
44.27
Variation Quotidienne
-1.14 -2.51%
Mensuellement
6.04%
Annuel
25.38%
Q2 Prévisions
43.06




La Marge Brute Sur Les Ventes Changement Date
Acadia Pharmaceuticals USD 257.76M 778K 2025-12
Agios Pharmaceuticals USD 18.09M 6.89M 2025-12
Akebia Therapeutics USD 47.28M 1.7M 2025-12
Amgen USD 6.48B 307M 2025-09
AstraZeneca USD 12.39B 5M 2025-12
Bayer EUR 5.35B 1.02B 2025-09
BioMarin Pharmaceutical USD 713.01M 81.81M 2025-12
Bristol-Myers Squibb USD 8.79B 110M 2025-09
Cytokinetics USD 17.76M 15.82M 2025-12
Eisai JPY 168.85B 17.02B 2025-12
Eli Lilly USD 14.59B 1.48B 2025-09
Esperion Therapeutics USD 140.59M 94.57M 2025-12
Exelixis USD 572.18M 7M 2025-12
Genmab DKK 977M 13M 2025-12
Glaxosmithkline GBP 8.75B 2.92B 2025-09
Incyte USD 1.39B 118.68M 2025-12
Ionis Pharmaceuticals USD 195M 40M 2025-12
MacroGenics USD 31.11M 30.14M 2025-12
Merck USD 13.42B 431M 2025-09
Moderna USD 226M 583M 2025-12
Nektar Therapeutics USD 21.81M 8.06M 2025-12
Neurocrine Biosciences USD 787.9M 7M 2025-12
Novartis USD 10.25B 570M 2025-12
Pfizer USD 3.54B 7.61B 2025-09
Puma Biotechnology USD 20.32M 24.85M 2024-09
Sanofi EUR 8.45B 3.02B 2025-12
Takeda JPY 790.55B 262.97B 2025-12
Ultragenyx Pharmaceutical USD 178M 46.06M 2025-12
Xencor USD 21M 22.61M 2025-09